Mesenchymal stem cell therapy (HepaStem) - Promethera Biosciences

Drug Profile

Mesenchymal stem cell therapy (HepaStem) - Promethera Biosciences

Alternative Names: hALDMSC - Promethera; HepaStem; Heterologous Human Adult Liver derived Progenitor Cells; HHALPC; human Adult Liver-Derived Mesenchymal Progenitor/Stem Cells - Promethera

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catholic University of Louvain
  • Developer Promethera Biosciences
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver disorders; Inborn urea cycle disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn urea cycle disorders; Liver failure
  • Phase I/II Liver disorders
  • Preclinical Non-alcoholic steatohepatitis
  • Research Haemophilia; Hepatic fibrosis
  • Discontinued Glycogen storage disease type I; Phenylketonuria

Most Recent Events

  • 24 Nov 2017 Discontinued - Preclinical for Glycogen storage disease type I in Belgium (IV)
  • 24 Nov 2017 Discontinued - Preclinical for Phenylketonuria in Belgium (IV)
  • 24 Nov 2017 Promethera Biosciences plans a long-term safety trial for Inborn urea cycle disorders and Liver disorders (In children, In adolescents, In adults, In the elderly) in November 2017 (NCT03343756)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top